Diabetes Start-Up Tethys Gets $25 Million To Speed Rollout Of Molecular Test
This article was originally published in The Pink Sheet Daily
Real-world impact of predictive test questioned. Skeptics say patients at risk will be loath to change, test or no test.
You may also be interested in...
Regulatory environment opens up, but alliances with Pharma have yet to take off.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.